{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:54:03Z","timestamp":1793843643675,"version":"4.6.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["UM1AI069412"],"award-info":[{"award-number":["UM1AI069412"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["UL1TR001102"],"award-info":[{"award-number":["UL1TR001102"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["UM1AI068618"],"award-info":[{"award-number":["UM1AI068618"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["UM1AI069481"],"award-info":[{"award-number":["UM1AI069481"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100003896","name":"Henry M Jackson Foundation for the Advancement of Military Medicine","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100003896","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"crossref","award":["W81XWH-17\u20130072"],"award-info":[{"award-number":["W81XWH-17\u20130072"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ragon Institute of MGH, MIT, and Harvard","id":[{"id":"https:\/\/ror.org\/053r20n13","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","award":["OPP1156831"],"award-info":[{"award-number":["OPP1156831"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Janssen Vaccines and Prevention"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Developing a cross-clade, globally effective HIV vaccine remains crucial for eliminating HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This placebo-controlled, double-blind, phase 1\/2a study enrolled healthy HIV-uninfected adults at low risk for HIV infection. They were randomized (1:4:1) to receive 4 doses of an adenovirus 26-based HIV-1 vaccine encoding 2 mosaic Gag and Pol, and 2 mosaic Env proteins plus adjuvanted clade C gp140 (referred to here as clade C regimen), bivalent protein regimen (clade C regimen plus mosaic gp140), or placebo. Primary end points were safety and antibody responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total 152\/155 participants (clade C, n = 26; bivalent protein, n = 103; placebo, n = 26) received \u22651 injection. The highest adverse event (AE) severity was grade 3 (local pain\/tenderness, 12%, 2%, and 0% of the respective groups; solicited systemic AEs, 19%, 15%, 0%). HIV-1 mosaic gp140-binding antibody titers were 79 595 ELISA units (EU)\/mL and 137 520 EU\/mL in the clade C and bivalent protein groups (P &amp;lt; .001) after dose 4 and 16 862 EU\/mL and 25 162 EU\/mL 6 months later. Antibody response breadth against clade C gp140 and clade C\/non-clade C gp120 was highest in the bivalent protein group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adding mosaic gp140 to the clade C regimen increased and broadened the elicited immune response without compromising safety or clade C responses.<\/jats:p>\n                    <jats:p>Clinical Trials Registration. NCT02935686.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiac445","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T01:29:03Z","timestamp":1667957343000},"page":"939-950","source":"Crossref","is-referenced-by-count":40,"title":["Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1\/2a Study"],"prefix":"10.1093","volume":"227","author":[{"given":"Daniel J","family":"Stieh","sequence":"first","affiliation":[{"name":"Janssen Vaccines and Prevention Leiden , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan H","family":"Barouch","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts , USA"},{"name":"Ragon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Comeaux","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention Leiden , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Sarnecki","sequence":"additional","affiliation":[{"name":"Janssen Vaccines , Bern , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E","family":"Stephenson","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R","family":"Walsh","sequence":"additional","affiliation":[{"name":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center , Boston, Massachusetts , USA"},{"name":"Brigham and Women's Hospital, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Sawant","sequence":"additional","affiliation":[{"name":"Department of Surgery, Center for Human Systems Immunology, and Duke Human Vaccine Institute, Duke University , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Heptinstall","sequence":"additional","affiliation":[{"name":"Department of Surgery, Center for Human Systems Immunology, and Duke Human Vaccine Institute, Duke University , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia D","family":"Tomaras","sequence":"additional","affiliation":[{"name":"Department of Surgery, Center for Human Systems Immunology, and Duke Human Vaccine Institute, Duke University , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G","family":"Kublin","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Juliana","family":"McElrath","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen W","family":"Cohen","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C","family":"De Rosa","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-9215","authenticated-orcid":false,"given":"Galit","family":"Alter","sequence":"additional","affiliation":[{"name":"Ragon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Department of Surgery, Center for Human Systems Immunology, and Duke Human Vaccine Institute, Duke University , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Montefiori","sequence":"additional","affiliation":[{"name":"Department of Surgery, Center for Human Systems Immunology, and Duke Human Vaccine Institute, Duke University , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mann","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Nijs","sequence":"additional","affiliation":[{"name":"Janssen Research and Development , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katleen","family":"Callewaert","sequence":"additional","affiliation":[{"name":"Janssen Research and Development , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A","family":"Goepfert","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Medicine, University of Alabama at Birmingham , Birmingham, Alabama , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srilatha","family":"Edupuganti","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Karita","sequence":"additional","affiliation":[{"name":"Rwanda Zambia HIV Research Group , Kigali , Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S","family":"Seaman","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R","family":"Baden","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G","family":"Pau","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention Leiden , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Schuitemaker","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention Leiden , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tomaka","sequence":"additional","affiliation":[{"name":"Janssen Research and Development , Titusville, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ASCENT\/HVTN118\/HPX2003 Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A","family":"Ake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Buchbinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor A","family":"Crowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelda","family":"Euler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Goedhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Keefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen F","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Nkolola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merlin L","family":"Robb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Rouphael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Scheppler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Sobieszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Van Tieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun K","family":"Phadke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"2023052214540167600_jiac445-B1","author":"World Health Organization"},{"key":"2023052214540167600_jiac445-B2","doi-asserted-by":"crossref","first-page":"590780","DOI":"10.3389\/fimmu.2020.590780","article-title":"Major scientific hurdles in HIV vaccine development: historical perspective and future directions","volume":"11","author":"Ng'uni","year":"2020","journal-title":"Front Immunol"},{"key":"2023052214540167600_jiac445-B3","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"2023052214540167600_jiac445-B4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1146\/annurev-immunol-080219-023629","article-title":"Vaccines and broadly neutralizing antibodies for HIV-1 prevention","volume":"38","author":"Stephenson","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"2023052214540167600_jiac445-B5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/infdis\/jiy212","article-title":"First-in-human randomized, controlled trial of mosaic HIV-1 immunogens delivered via a modified vaccinia Ankara vector","volume":"218","author":"Baden","year":"2018","journal-title":"J Infect Dis"},{"key":"2023052214540167600_jiac445-B6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nm.2089","article-title":"Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys","volume":"16","author":"Barouch","year":"2010","journal-title":"Nat Med"},{"key":"2023052214540167600_jiac445-B7","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"key":"2023052214540167600_jiac445-B8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nm1461","article-title":"Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants","volume":"13","author":"Fischer","year":"2007","journal-title":"Nat Med"},{"key":"2023052214540167600_jiac445-B9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2013.09.061","article-title":"Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys","volume":"155","author":"Barouch","year":"2013","journal-title":"Cell"},{"key":"2023052214540167600_jiac445-B10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1126\/science.aab3886","article-title":"Protective efficacy of adenovirus\/protein vaccines against SIV challenges in rhesus monkeys","volume":"349","author":"Barouch","year":"2015","journal-title":"Science"},{"key":"2023052214540167600_jiac445-B11","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3018(20)30001-1","article-title":"Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010\/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22)","volume":"7","author":"Stephenson","year":"2020","journal-title":"Lancet HIV"},{"key":"2023052214540167600_jiac445-B12","doi-asserted-by":"crossref","first-page":"228ra39","DOI":"10.1126\/scitranslmed.3007730","article-title":"Vaccine-induced Env V1\u2013V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination","volume":"6","author":"Yates","year":"2014","journal-title":"Sci Transl Med"},{"key":"2023052214540167600_jiac445-B13","doi-asserted-by":"crossref","first-page":"e87572","DOI":"10.1371\/journal.pone.0087572","article-title":"Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection","volume":"9","author":"Zolla-Pazner","year":"2014","journal-title":"PLoS One"},{"key":"2023052214540167600_jiac445-B14","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"2023052214540167600_jiac445-B15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/infdis\/jiac260","article-title":"Analysis of the HVTN 702 phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk","volume":"226","author":"Moodie","year":"2022","journal-title":"J Infect Dis"},{"key":"2023052214540167600_jiac445-B16","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2352-3018(20)30229-0","article-title":"Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1\/2a study","volume":"7","author":"Baden","year":"2020","journal-title":"Lancet HIV"},{"key":"2023052214540167600_jiac445-B17","article-title":"Phase 2b efficacy trial of mosaic HIV-1 vaccine regimen in African women (Imbokodo)","author":"Gray","year":"2022"},{"key":"2023052214540167600_jiac445-B18","author":"Barouch","year":"2019"},{"key":"2023052214540167600_jiac445-B19","doi-asserted-by":"crossref","first-page":"9538","DOI":"10.1128\/JVI.01739-14","article-title":"Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer","volume":"88","author":"Nkolola","year":"2014","journal-title":"J Virol"},{"key":"2023052214540167600_jiac445-B20","doi-asserted-by":"crossref","first-page":"e01843-17","DOI":"10.1128\/JVI.01843-17","article-title":"HIV-1 envelope glycoproteins from diverse clades differentiate antibody responses and durability among vaccinees","volume":"92","author":"Yates","year":"2018","journal-title":"J Virol"},{"key":"2023052214540167600_jiac445-B21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"2023052214540167600_jiac445-B22","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tube.2016.09.004","article-title":"Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations","volume":"101","author":"Sharpe","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"key":"2023052214540167600_jiac445-B23","doi-asserted-by":"crossref","first-page":"eaaw1673","DOI":"10.1126\/scitranslmed.aaw1673","article-title":"Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial","volume":"11","author":"Kallas","year":"2019","journal-title":"Sci Transl Med"},{"key":"2023052214540167600_jiac445-B24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M20-5306","article-title":"A double-blind, randomized, placebo-controlled phase 1 study of Ad26.ZIKV.001, an Ad26-vectored anti-Zika virus vaccine","volume":"174","author":"Salisch","year":"2021","journal-title":"Ann Intern Med"},{"key":"2023052214540167600_jiac445-B25","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMc2108829","article-title":"Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination","volume":"385","author":"Barouch","year":"2021","journal-title":"N Engl J Med"},{"key":"2023052214540167600_jiac445-B26","author":"Food and Drug Administration"},{"key":"2023052214540167600_jiac445-B27","doi-asserted-by":"crossref","first-page":"680","DOI":"10.15585\/mmwr.mm7018e2","article-title":"Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine\u2014United States, March\u2013April 2021","volume":"70","author":"Shay","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023052214540167600_jiac445-B28","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2031499","article-title":"Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults","volume":"384","author":"Gray","year":"2021","journal-title":"N Engl J Med"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiac445\/47501671\/jiac445.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/227\/8\/939\/50416542\/jiac445.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/227\/8\/939\/50416542\/jiac445.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T10:54:51Z","timestamp":1684752891000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/227\/8\/939\/6812747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,11,9]]},"published-print":{"date-parts":[[2023,4,18]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac445","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,15]]},"published":{"date-parts":[[2022,11,9]]}}}